These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

237 related items for PubMed ID: 21909140

  • 1. Overexpression of androgen receptor enhances the binding of the receptor to the chromatin in prostate cancer.
    Urbanucci A, Sahu B, Seppälä J, Larjo A, Latonen LM, Waltering KK, Tammela TL, Vessella RL, Lähdesmäki H, Jänne OA, Visakorpi T.
    Oncogene; 2012 Apr 26; 31(17):2153-63. PubMed ID: 21909140
    [Abstract] [Full Text] [Related]

  • 2. Integration of cap analysis of gene expression and chromatin immunoprecipitation analysis on array reveals genome-wide androgen receptor signaling in prostate cancer cells.
    Takayama K, Tsutsumi S, Katayama S, Okayama T, Horie-Inoue K, Ikeda K, Urano T, Kawazu C, Hasegawa A, Ikeo K, Gojyobori T, Ouchi Y, Hayashizaki Y, Aburatani H, Inoue S.
    Oncogene; 2011 Feb 03; 30(5):619-30. PubMed ID: 20890304
    [Abstract] [Full Text] [Related]

  • 3. Androgen-regulated miR-32 targets BTG2 and is overexpressed in castration-resistant prostate cancer.
    Jalava SE, Urbanucci A, Latonen L, Waltering KK, Sahu B, Jänne OA, Seppälä J, Lähdesmäki H, Tammela TL, Visakorpi T.
    Oncogene; 2012 Oct 11; 31(41):4460-71. PubMed ID: 22266859
    [Abstract] [Full Text] [Related]

  • 4. Androgen receptor overexpression alters binding dynamics of the receptor to chromatin and chromatin structure.
    Urbanucci A, Marttila S, Jänne OA, Visakorpi T.
    Prostate; 2012 Aug 01; 72(11):1223-32. PubMed ID: 22212979
    [Abstract] [Full Text] [Related]

  • 5. Y-box binding protein-1 promotes castration-resistant prostate cancer growth via androgen receptor expression.
    Shiota M, Takeuchi A, Song Y, Yokomizo A, Kashiwagi E, Uchiumi T, Kuroiwa K, Tatsugami K, Fujimoto N, Oda Y, Naito S.
    Endocr Relat Cancer; 2011 Aug 01; 18(4):505-17. PubMed ID: 21652770
    [Abstract] [Full Text] [Related]

  • 6. Increased expression of androgen receptor sensitizes prostate cancer cells to low levels of androgens.
    Waltering KK, Helenius MA, Sahu B, Manni V, Linja MJ, Jänne OA, Visakorpi T.
    Cancer Res; 2009 Oct 15; 69(20):8141-9. PubMed ID: 19808968
    [Abstract] [Full Text] [Related]

  • 7. Androgen receptor amplification is reflected in the transcriptional responses of Vertebral-Cancer of the Prostate cells.
    Makkonen H, Kauhanen M, Jääskeläinen T, Palvimo JJ.
    Mol Cell Endocrinol; 2011 Jan 01; 331(1):57-65. PubMed ID: 20728506
    [Abstract] [Full Text] [Related]

  • 8. Steroidogenic enzyme AKR1C3 is a novel androgen receptor-selective coactivator that promotes prostate cancer growth.
    Yepuru M, Wu Z, Kulkarni A, Yin F, Barrett CM, Kim J, Steiner MS, Miller DD, Dalton JT, Narayanan R.
    Clin Cancer Res; 2013 Oct 15; 19(20):5613-25. PubMed ID: 23995860
    [Abstract] [Full Text] [Related]

  • 9. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence.
    Unni E, Sun S, Nan B, McPhaul MJ, Cheskis B, Mancini MA, Marcelli M.
    Cancer Res; 2004 Oct 01; 64(19):7156-68. PubMed ID: 15466214
    [Abstract] [Full Text] [Related]

  • 10. Key targets of hormonal treatment of prostate cancer. Part 1: the androgen receptor and steroidogenic pathways.
    Vis AN, Schröder FH.
    BJU Int; 2009 Aug 01; 104(4):438-48. PubMed ID: 19558559
    [Abstract] [Full Text] [Related]

  • 11. Regulation of FGF8 expression by the androgen receptor in human prostate cancer.
    Gnanapragasam VJ, Robson CN, Neal DE, Leung HY.
    Oncogene; 2002 Aug 01; 21(33):5069-80. PubMed ID: 12140757
    [Abstract] [Full Text] [Related]

  • 12. Androgen receptor-dependent regulation of Bcl-xL expression: Implication in prostate cancer progression.
    Sun A, Tang J, Hong Y, Song J, Terranova PF, Thrasher JB, Svojanovsky S, Wang HG, Li B.
    Prostate; 2008 Mar 01; 68(4):453-61. PubMed ID: 18196538
    [Abstract] [Full Text] [Related]

  • 13. Amyloid precursor protein is a primary androgen target gene that promotes prostate cancer growth.
    Takayama K, Tsutsumi S, Suzuki T, Horie-Inoue K, Ikeda K, Kaneshiro K, Fujimura T, Kumagai J, Urano T, Sakaki Y, Shirahige K, Sasano H, Takahashi S, Kitamura T, Ouchi Y, Aburatani H, Inoue S.
    Cancer Res; 2009 Jan 01; 69(1):137-42. PubMed ID: 19117996
    [Abstract] [Full Text] [Related]

  • 14. PC3, but not DU145, human prostate cancer cells retain the coregulators required for tumor suppressor ability of androgen receptor.
    Litvinov IV, Antony L, Dalrymple SL, Becker R, Cheng L, Isaacs JT.
    Prostate; 2006 Sep 01; 66(12):1329-38. PubMed ID: 16835890
    [Abstract] [Full Text] [Related]

  • 15. FOXP1 is an androgen-responsive transcription factor that negatively regulates androgen receptor signaling in prostate cancer cells.
    Takayama K, Horie-Inoue K, Ikeda K, Urano T, Murakami K, Hayashizaki Y, Ouchi Y, Inoue S.
    Biochem Biophys Res Commun; 2008 Sep 19; 374(2):388-93. PubMed ID: 18640093
    [Abstract] [Full Text] [Related]

  • 16. Identification of novel androgen receptor target genes in prostate cancer.
    Jariwala U, Prescott J, Jia L, Barski A, Pregizer S, Cogan JP, Arasheben A, Tilley WD, Scher HI, Gerald WL, Buchanan G, Coetzee GA, Frenkel B.
    Mol Cancer; 2007 Jun 06; 6():39. PubMed ID: 17553165
    [Abstract] [Full Text] [Related]

  • 17. Increased androgen receptor transcription: a cause of castration-resistant prostate cancer and a possible therapeutic target.
    Shiota M, Yokomizo A, Naito S.
    J Mol Endocrinol; 2011 Aug 06; 47(1):R25-41. PubMed ID: 21504942
    [Abstract] [Full Text] [Related]

  • 18. Testosterone boosts for treatment of castration resistant prostate cancer: an experimental implementation of intermittent androgen deprivation.
    Thelen P, Heinrich E, Bremmer F, Trojan L, Strauss A.
    Prostate; 2013 Nov 06; 73(15):1699-709. PubMed ID: 23868789
    [Abstract] [Full Text] [Related]

  • 19. Identification of EP4 as a potential target for the treatment of castration-resistant prostate cancer using a novel xenograft model.
    Terada N, Shimizu Y, Kamba T, Inoue T, Maeno A, Kobayashi T, Nakamura E, Kamoto T, Kanaji T, Maruyama T, Mikami Y, Toda Y, Matsuoka T, Okuno Y, Tsujimoto G, Narumiya S, Ogawa O.
    Cancer Res; 2010 Feb 15; 70(4):1606-15. PubMed ID: 20145136
    [Abstract] [Full Text] [Related]

  • 20. Androgen receptor (AR) aberrations in castration-resistant prostate cancer.
    Waltering KK, Urbanucci A, Visakorpi T.
    Mol Cell Endocrinol; 2012 Sep 05; 360(1-2):38-43. PubMed ID: 22245783
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.